↑Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID21948594.edit
↑Danysz W, Plaznik A, Kostowski W, Malatynska E, Järbe TU, Hiltunen AJ, Archer T (January 1988). „Comparison of desipramine, amitriptyline, zimeldine and alaproclate in six animal models used to investigate antidepressant drugs”. Pharmacology & Toxicology62 (1): 42–50. PMID2965810.
↑Jäkälä P, Sirviö J, Riekkinen P, Valjakka A, Riekkinen P (1992). „The effects of alaproclate and p-chlorophenylalanine on cued navigation performance in rats”. Journal of Neural Transmission. Parkinson's Disease and Dementia Section4 (1): 43–52. PMID1531758.
↑A Wilkinson, M Courtney, A Westlind-Danielsson, G Hallnemo and K E Akerman (December 1994). „Alaproclate acts as a potent, reversible and noncompetitive antagonist of the NMDA receptor coupled ion flow”. JPET271 (3): 1314–1319.
↑K L Nicholson and R L Balster (2003-04-23). „Evaluation of the phencyclidine-like discriminative stimulus effects of novel NMDA channel blockers in rats”. Psychopharmacology.